Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials.
Download and listen wherever you listen to podcasts (Apple Podcasts, Google Podcasts, Tune In, Listen Notes, Podcast Addict).
To listen in AGA University, click Launch Course.
Hosts:
Erin Forster, MD, MPH, Associate Professor
Division of Gastroenterology and Hepatology
Medical University of South Carolina
Charleston, SC
Ayanna Lewis, MD, Assistant Professor
Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, NY
Episode breakdown:
Episode 1: Diversity in IBD Trials: Start with our workforce
Our hosts Drs. Erin Forster and Ayanna Lewis are joined by guests Drs. Freddy Caldera and Jana Al Hashash to discuss how diversifying participation in clinical trials starts with diversifying our workforce.
Episode 2: Diversity in IBD Trials: Changing how we talk to patients
Drs. Erin Forster and Ayanna Lewis are joined by guest Melodie Narain-Blackwell, the founder and president of Color of Crohn’s & Chronic Illness (COCCI) to discuss how to talk about clinical research with patients.
Episode 3: Diversity in IBD Trials: Bringing research to the community
Co-host Dr. Erin Forster is joined by guest Kenneth Getz, founder of CISCRP to discuss how to bring awareness of and education on clinical research to the community.
Episode 4: Diversity in IBD Trials: The community GI perspective
Co-host Dr. Ayanna Lewis is joined by guest Dr. Erica Cohen, to discuss the community GI’s perspective on clinical trials.
Episode 5: Diversity in IBD Trials: The role of the CRO
Co-host Dr. Erin Forster is joined by guest Dr. Gabriela Radulescu to discuss how contract research organizations (CROs) are working with investigators and sponsors to increase the diversity of patients enrolling in clinical trials.
Episode 6: Diversity in IBD Trials: How artificial intelligence may help
In this supersized episode, co-host Dr. Ayanna Lewis is joined by guest Dr. Ryan Stidham to explore how artificial intelligence may help address challenges with participant recruitment for clinical trials, while also discussing the role of AI in the field of gastroenterology more broadly.
Disclosures
Dr. Dubinsky reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Prometheus Laboratories; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Ali reports the following financial relationships:
Advisory Board: AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Consultant: AbbVie Inc.; Boehringer Ingelheim; E.R. Squibb & Sons, L.L.C.; and Fresenius Kabi USA
Research Support: AbbVie Inc.; Arena Pharmaceuticals; AstraZeneca; and Celgene Corporation
Speakers Bureau: AbbVie Inc.; E.R. Squibb & Sons, L.L.C.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Long reports the following financial relationships:
Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE
Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Sept. 29, 2024
Commercial support:
This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.